Is it though?I sshould know better than to preach pragmatism on this forum, but, what do you think a trial size history for pharma would be.
If I was a lawyer I'd definitely be asking why my client has to have large trials and MSB gets to say ignore the old ones and look at the 55 patient trial.
MSBs job is to explain why it's okay, say for instance that safety is not a concern and so efficacy doesn't need as big a dataset?
Fingers crossed for tonight though.
Ryoncil: ODAC/FDA Meeting Discussion, page-22
-
- There are more pages in this discussion • 2,025 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.19 |
Change
0.085(7.69%) |
Mkt cap ! $1.358B | |||
| Open | High | Low | Value | Volume |
| $1.10 | $1.20 | $1.09 | $13.21M | 11.37M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 15000 | $1.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.19 | 75212 | 5 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |